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Background: Provision of contraceptive methods with minimal side effects will enhance uptake of contraception particularly in 
Nigeria where contraceptive prevalence rate remains low. The safety profile of ImplanonR, a long‑acting hormonal subdermal 
contraceptive containing etonogestrel, has not been adequately evaluated among Nigerian women.
Objective: To assess the effects of etonogestrel subdermal implant (ImplanonR) on lipid profile among Nigerian women.
Materials and Methods: The study was a longitudinal follow‑up of 54 consenting women selected over a 6‑month period at 
the Family Planning Clinic of the University College Hospital, Ibadan. After ImplanonR insertion, each woman was followed‑up 
monthly for a period of 12 months. Fasting venous blood samples were collected for quantification of serum lipids prior to 
insertion of the implant, then at 1st, 3rd, 6th, 9th, and 12th months of follow‑up.
Results: The mean age of the women was 34.4 ± 5.6 with a range of 22–47 years. The modal number of children was 2 
ranging from 1 to 6. Total cholesterol (TC) levels showed a general tendency toward a rise. The rise was, however, only 
significant in the 3rd and 12th months of use. Serum triglycerides showed a tendency toward reduced levels, which were only 
significant at the 6th and 9th months of use. High‑density lipoprotein (HDL) levels were consistently and significantly elevated 
above baseline levels. Beyond the 3rd month, low‑density lipoprotein (LDL) levels were lower but not significantly compared with 
baseline levels. HDL/TC and HDL/LDL ratios were consistently and significantly elevated in comparison with baseline values.
Conclusion: Etonogestrel implant seems to cause significant effects on the lipid profile of Nigerian women. The increases 
were mainly in the HDL fraction, which suggests that the atherogenic and cardiovascular disease risks are reduced. We 
recommend larger studies to confirm our findings.
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Introduction
Recent developments in hormonal contraceptives have been 
directed toward lowering the dosage of steroid hormones to 
minimize their risk potentials: ischemic heart disease, stroke, 
myocardial infarction, thromboembolism, and changes in the 
blood clotting mechanism.[1]
Contraceptive implants are a milestone in contraceptive 
delivery systems for improving the quality of family planning 
programs. Up to 10 potential contraceptive implants have 
been tested in 5,000 women in the last three decades.
Their introduction was necessitated to ameliorate some side 
effects associated with previous contraceptives. Subdermal 
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contraceptive implants provide constant delivery of a very 
low dose of progestin that offers effective contraception. 
The six-capsule levonorgestrel system (Norplant) was the 
first subdermal contraceptive implant introduced and it is 
estimated that approximately nine million women worldwide 
have used or are using this method.[2] Unlike other hormonal 
delivery systems, they do not cause unnecessary peaks in 
progestin levels and do not use estrogens, and thus, their 
health risks are minimal.
Thromboembolism has been shown to be the most fatal 
complication,[3] and over 75% of deaths result from ischemic 
and hypertensive heart diseases.[4] One of the major causes of 
morbidity and mortality worldwide is cardiovascular disease. 
In 2008, cardiovascular disease accounted for 31% of all global 
deaths, of which 80% occurred in developing countries.[5] 
Metabolic risk factors include obesity, hypertension, type 2 
diabetes mellitus, high serum cholesterol, and dyslipidemia.[6]
Estrogen and progesterone levels present in contraceptives 
have different and sometimes opposite effect on lipid 
metabolism. Estrogen increases serum level of high-density 
lipoprotein cholesterol (HDL-C) whereas progesterone 
reduces HDL-C level and increases serum low-density 
lipoprotein cholesterol (LDL-C) leading to increase chances 
of thromboembolism.[7] Some of the metabolic risk factors 
for cardiovascular disease can arise consequent to the use 
of hormonal contraceptives.
Progestin hormonal contraceptives have been implicated 
in the possible alteration of lipid levels and transport 
mechanisms that are responsible for the risk of arterial 
thrombosis.[8] Similarly, 19-nor-steroid derivatives such 
as levonorgestrel have been reported to have a strong 
androgenic effect and may cause a significant alteration in the 
lipid profile thus, worsening the atherogenic indices.[9] These 
shortcomings led to the discontinuation of Norplant[10] and 
heralded the universal use of ImplanonR. The vast majority 
of evidence on implants arises from studies of levonorgestrel 
and other progestins and permit similar drug release from 
only one to two implants rather than six, leading to faster 
and easier placement and removal.[11]
Low dose progestin-only contraceptives may have deleterious 
effects on lipid profile. A study comparing the effects of 
non-hormonal contraceptive, combined oral contraceptive, 
and depo-medroxyprogesterone acetate (DMPA) on lipids 
reported that the depo-medroxyprogesterone acetate users 
gained significantly more weight compared with other groups 
and the patterns of change in LDL-C and triglycerides were 
not significantly different among groups. The significant 
change in HDL-C was observed only in combined oral 
contraceptive and nonhormonal contraceptive groups.[12] 
However, in a study by Okeke et al.[13] There was a significant 
change in triglyceride and LDL-C levels when comparing the 
effects of injectable and oral hormonal contraceptives on 
lipid profile. There was increase in the triglyceride levels 
but decrease in LDL-C levels in the injectable contraceptive 
group. There was no statistically significant change in 
total cholesterol and HDL-C levels in women on oral 
contraceptives but HDL-C was significantly increased in 
injectable contraceptive group.[13] A study evaluated effects 
of Norplant compared with depo-medroxyprogesterone 
acetate and low-dose oral contraceptives on lipid profile. 
There was decrease in the total cholesterol and LDL-C levels 
in all groups except depo-medroxyprogesterone acetate 
group where there was an increase. Triglycerides only 
increased in the oral contraceptive group. HDL-C increased 
with the oral contraceptives and decreased with Norplant 
and depo-medroxyprogesterone.[14]
Implanon is a reversible, long-acting, subdermal hormonal 
contraceptive with etonorgestrel (3-keto-desogestrel) as active 
ingredient. It is a progestogen-only method using a single-rod 
system with a disposable applicator. The method is suitable 
for a wide range of women: to postpone a first pregnancy, 
“space” pregnancies, and provide reversible, long-term 
contraception when the desired family size is reached. Each 
ImplanonR implant contains 68 mg of etonogestrel, the active 
metabolite of desogestrel, which is used in COC pills. The 
clinical pharmacology for desogestrel and etonogestrel has 
been well established. Implanon avoids the first-pass effect 
of orally taken hormonal contraceptives through the liver and 
has a potentially different clinical pharmacology.[11]
Since the introduction of Implanon, its effects on the lipid 
profile of users have not been comprehensively evaluated. 
The use of hormonal contraceptives has been associated with 
increased cardiovascular risk,[5] so also progestins have been 
associated with an increased risk of arterial thrombosis.[8] 
Race and ethnic groups may alter effect of progestins on lipid 
profile.[15] Studies on effects of Implanon on lipid metabolism 
serum immunoglobulins, albumin, and total proteins have 
not been reported in Nigeria. In view of these, we decide to 
determine the safety, considering the cardiovascular risks of 
ImplanonR use, among Nigerian women as regards its effects 
on their serum lipid profile.
Materials and Methods
This was a longitudinal study of apparently healthy clients 
of the Family Planning Clinic, University College Hospital, 
Ibadan. The sample size was calculated using previously 
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established methods.[16] The sample size was based on 
techniques described by Pocock.[17] Assuming a statistical 
power of 0.9 with 95% confidence, the minimum number 
of clients required to demonstrate a 15% change in serum 
level of cholesterol with a presumed drop-out rate of 20% 
is 44. The recruitment of subjects was over 6 months. Sixty 
consecutive clients were recruited. They were followed-up 
monthly for a period of 12 months.
Eligibility criteria included being women of reproductive 
age (18–45 years) who were not on any other medication. 
They had no contraindications to the use of hormonal 
contraceptives and were willing to use hormonal contraception 
as a method of fertility control for at least 1 year. Their 
menstrual cycles during the previous 3 months had been 
regular and they were living in the locality to allow adequate 
follow-up. They used ImplanonR alone for contraception.
The exclusion criteria were previous history or on-going 
thrombo-embolic disease, use of hormonal contraception 
in the preceding 6 months, presence of varicose veins or 
hypertension (BP ≥ 140/90 mm Hg), presence of liver disease 
or endocrine condition, especially diabetes mellitus. Others 
were the presence of mental disorders or known allergy to 
silastic materials or heavy smoking. Ethical approval was 
obtained from joint UI/UCH ethical committee.
After recruitment of participants, written informed consent 
was obtained followed by documentation of baseline 
characteristics including weight, height, and blood 
pressure. Baseline blood sample (10 ml of fasting venous 
blood) was taken and serum lipids: total cholesterol (TC), 
triglycerides (TG), LDL-C, and HDL-C were measured. The 
data were recorded on a proforma.
Each subject was seen between 8:00 and 9:00 a.m., and 
the insertion was performed by a trained personnel with 
the woman lying on her back using an aseptic technique. 
The insertion site was the sulcus bicipitalis medialis of the 
nondominant arm. After skin preparation and draping, 1% 
lignocaine local anesthetic infiltration was applied. The skin 
of the site was stretched and the preloaded inserter was 
used to penetrate the skin with the implant deposited in the 
subdermal area just like the reverse of an injection.
The follow-up involved monthly visits up to 12 months with 
a menstrual diary kept by each participant. At each visit, the 
participant’s clinical status was reviewed with the findings 
carefully recorded in the follow-up cards. The menstrual 
diary was designed to keep a record of the menstrual flow 
and bleeding episodes. Fasting venous blood sample was 
collected at the 1st, 3rd, 6th, 9th, and 12th months following 
insertion and the participant’s weight was also measured.
Fasting venous blood (10 ml) was collected from the antecubital 
vein of either arm, after application of a tourniquet, into an 
anticoagulant-free tube. After clot retraction, the bottle was 
spun at 3,000 rpm for 5 min followed by separation of sera 
and storage at ‒20°C until analysis was carried out at the 
end of the study. Serum total cholesterol and triglycerides 
were measured with a Hitachi 704 auto analyser (Boeringer 
Mannheim, Mannheim, Germany) using fully enzymatic 
procedures as in the commercial kits supplied by the 
company.[18] HDLs were measured after selective precipitation 
of LDL using phosphotungstic and magnesium chloride 
reagents. LDL was also estimated according to the method 
of Friedwald et al.[19]
We employed Microsoft Excel (Microsoft, Redmond, WA) 
version 8 for data entry whereas data analysis was performed 
with SPSS version 17. Mean levels at the 1st, 3rd, 6th, 9th, and 
12th months for the various parameters were compared 
with the preinsertion value using the independent “t” test 
to determine the level of significance of any observed 
differences. The value of P < 0.05 was regarded as significant.
Results
The study was conducted between June 2008 and June 2010. 
Of the 60 women recruited, 54 women completed the study. 
The mean age of the women was 34.4 ± 5.6 years whereas 
the range was 22–47 years. The modal number of children 
was 2 with a range of 1–6. The serum levels of the various 
lipid fractions are as reflected in Tables 1 and 2.
Discussion
ImplanonR is acceptable to Nigerian women. In Jos, 
ImplanonR was accepted by almost 15% of contraceptive 
users with high continuation rates.[20] In Benin, no 
remarkable changes in weight or BP were reported among 
users.[21] In a recent study,[22] it was found that implanon 
users had higher diastolic blood pressure than the oral 
contraceptive or injectable contraceptive users. Women 
using oral contraceptives for more than 8 years presented 
higher age-adjusted blood pressure levels than women 
using oral contraceptives for shorter periods. An increase in 
diastolic blood pressure is a common feature of hormonal 
contraceptive use.
Menstrual changes are the major issues with the ImplanonR 
users. Its biochemical or hormonal effects among Nigerian 
women has not been fully evaluated. Studies in Europe[23,24] and 
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Asia[25,26] reveal no negative effects on cardiovascular risk factors. 
Implanon tended to be associated with a reduction in plasma 
lipids in most reports have provided assurance about safety 
of Implanon. In the Toronto Nutrigenomics and Health Study, 
which involved 783 subjects, lipid metabolism biomarkers were 
statistically significantly higher among hormonal contraceptive 
users.[27] Our data show variable changes in lipid profile. HDLs 
showed significant trend toward a rise from baseline values. 
Both HDL/total cholesterol ratio and HDL/LDL ratios showed 
consistent and significant rise from baseline levels.
It appears that hormonal contraceptive use indirectly affects 
cardiovascular risk through mechanisms involving weight gain 
and obesity. Obesity has been shown to reduce the efficacy of 
contraceptives because of their pharmacokinetic alterations. 
However, obesity is a well-established cardiovascular risk 
factor, associated with cardiometabolic risk factors including 
hypertension, type 2 diabetes, and high serum cholesterol.[6] 
The relationship between abnormal lipid levels and risk for 
coronary heart disease and myocardial infarction in all regions 
of the world has been established.[28] Dyslipidemia typified 
by high triglycerides and high LDLs as well as LDL/HDL 
ratios predispose subjects to atherosclerosis and myocardial 
infarction. In this study, the LDL remained unchanged; 
triglycerides were reduced whereas the HDL levels were 
increased. This pattern contradicts the reported trend in the 
literature. If this trend is confirmed by larger studies, it may be 
beneficial in women with a history of lipid disorders. This may 
then improve the uptake and continuation rates of ImplanonR.
Conclusion
ImplanonR is acceptable to Nigerian women. It has some 
demonstrable effects on lipid profile. The increases 
were mainly in the HDL fraction, which suggests that the 
atherogenic and cardiovascular disease risks are reduced. 
Larger studies are required to establish its effects on lipid 
profiles among Nigerian women. If the safety and biochemical 
benefits are proven, then it may potentially improve uptake 
and acceptance of this method.
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